Who are AP09004's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methylphenidate, aripiprazole, and combination, combination with dopamine agonist cabergoline, Intramuscular olanzapine, aripiprazole, Flupentixol melitracen tablets, paliperidone clozapine, Standard of Care Oral antipsychotics.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ap09004.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AP09004 — Competitive Intelligence Brief

AP09004 (AP09004) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine receptor antagonist. Area: Neurology.

phase 2 Dopamine receptor antagonist D2 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AP09004 (AP09004) — Intec Pharma Ltd.. AP09004 is a drug that targets the dopamine receptor D2.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AP09004 TARGET	AP09004	Intec Pharma Ltd.	phase 2	Dopamine receptor antagonist	D2 receptor
Methylphenidate, aripiprazole, and combination	Methylphenidate, aripiprazole, and combination	Tri-Service General Hospital	marketed	Stimulant and atypical antipsychotic combination	Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor
combination with dopamine agonist cabergoline	combination with dopamine agonist cabergoline	Ludwig-Maximilians - University of Munich	marketed	Dopamine agonist	Dopamine D2 receptor
Intramuscular olanzapine, aripiprazole	Intramuscular olanzapine, aripiprazole	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole)
Flupentixol melitracen tablets	Flupentixol melitracen tablets	Peking University Third Hospital	marketed	Typical antipsychotic + tricyclic antidepressant combination	Dopamine D2 receptor (flupentixol); norepinephrine and serotonin transporters (melitracen)
paliperidone clozapine	paliperidone clozapine	Universidad Nacional de Rosario	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Standard of Care Oral antipsychotics	Standard of Care Oral antipsychotics	University of Utah	marketed	Antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine receptor antagonist class)

Idorsia Pharmaceuticals Ltd. · 1 drug in this class
Intec Pharma Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AP09004 — Competitive Intelligence Brief. https://druglandscape.com/ci/ap09004. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab